A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)

BACKGROUND: In a Phase III randomized, double-blind, placebo-controlled study of CMV-seropositive HCT recipients, letermovir prophylaxis significantly reduced the incidence of clinically significant CMV infections (CS-CMVi) through 24 weeks post-HCT. We investigated the impact of letermovir prophyla...

Descripción completa

Detalles Bibliográficos
Autores principales: Maertens, Johan, Schmitt, Michael, Marty, Francisco M, Ljungman, Per, Chemaly, Roy F, Kartsonis, Nicholas A, Butterton, Joan, Wan, Hong, Teal, Valerie L, Sarratt, Kendra, Murata, Yoshihiko, Leavitt, Randi Y, Badshah, Cyrus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631942/
http://dx.doi.org/10.1093/ofid/ofx163.726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631942/
http://dx.doi.org/10.1093/ofid/ofx163.726

Ejemplares similares